Bay Street News, March, 2024

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the […]

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the […]

– Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 – – Announced […]

IRVINE, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of compute and connectivity IoT […]

LYON, France, March 6, 2024 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, […]

NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date […]

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) — Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading […]

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 06, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a leader […]

TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage […]

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a […]